Clinical Trial Update: A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 [Phase 1]

View source ↗

Summary

This first-in-human Phase 1 trial of PF-06755347 evaluating safety, tolerability, and pharmacokinetics was terminated, and results have been posted. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• PF-06755347

Snippet

Sponsor: Pfizer | Conditions: Healthy, Primary Immune Thrombocytopenia | Phase 1 | Status: TERMINATED | Results posted: 2024-07-05